Skip to content
Home/Companies/Biotech/Trishula Therapeutics
Trishula Therapeutics

Trishula Therapeutics

Biotech·US·Active·6yr hold
Entry
2020
Hold
6yr
Status
Active

Who owns Trishula Therapeutics?

Trishula Therapeutics is currently owned by Abingworth through Abingworth Bioventures VII (2018 vintage), since 2020.

Hand-verified · updated 2026-06-10

Abingworth
Investor
Abingworth
Abingworth Bioventures VII · 2018 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusActive
Websitewww.trishulatx.com

More from Abingworth Bioventures VII

Other portfolio companies in the same fund.

Adicet Bio
Adicet Bio
Active
BiotechUS· 2021
Soteria Biotherapeutics
Soteria Biotherapeutics
Active
HealthcareUS· 2021
Atsena Therapeutics
Atsena Therapeutics
Active
BiotechUS· 2020
Orbus Therapeutics
Orbus Therapeutics
Active
HealthcareUS· 2020
Q32 Bio
Exited 2024
BiotechUS· 2020
Scorpion Therapeutics
Scorpion Therapeutics
Exited 2025
BiotechUS· 2020
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Trishula Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Trishula Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue